Your browser doesn't support javascript.
loading
Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
Pasqualetti, Francesco; Pace, Andrea; Gonnelli, Alessandra; Villani, Veronica; Cantarella, Martina; Delishaj, Durim; Vivaldi, Caterina; Molinari, Alessandro; Montrone, Sabrina; Pellerino, Alessia; Franchino, Federica; Baldaccini, Davide; Lombardi, Giuseppe; Lolli, Ivan; Catania, Francesca; Bazzoli, Elena; Morganti, Riccardo; Fabi, Alessandra; Zagonel, Vittorina; Bocci, Guido; Fabrini, Maria Grazia; Rudà, Roberta; Soffietti, Riccardo; Paiar, Fabiola.
Afiliação
  • Pasqualetti F; Division of Radiation Oncology.
  • Pace A; Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome.
  • Gonnelli A; Division of Radiation Oncology.
  • Villani V; Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome.
  • Cantarella M; Division of Radiation Oncology.
  • Delishaj D; Division of Radiation Oncology.
  • Vivaldi C; Departments of Oncology, Division of Medical Oncology.
  • Molinari A; Division of Radiation Oncology.
  • Montrone S; Division of Radiation Oncology.
  • Pellerino A; Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin.
  • Franchino F; Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin.
  • Baldaccini D; Division of Radiation Oncology.
  • Lombardi G; Department of Clinical and Experimental Oncology, Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova.
  • Lolli I; Medical Oncology, Saverio de Bellis IRCCS Hospital, Castellana Grotte.
  • Catania F; Department of Neurology, University Hospital of Verona, Verona, Italy.
  • Bazzoli E; Department of Neurology, University Hospital of Verona, Verona, Italy.
  • Morganti R; Department of Experimental and Clinical Medicine, Section of Statistics, Pisa University Hospital.
  • Fabi A; Neuro-Oncology Unit, Regina Elena Cancer Institute, Rome.
  • Zagonel V; Department of Clinical and Experimental Oncology, Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova.
  • Bocci G; Clinical and Experimental Medicine, Division of Pharmacology, University of Pisa, Pisa.
  • Fabrini MG; Division of Radiation Oncology.
  • Rudà R; Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin.
  • Soffietti R; Department of Neuro-Oncology, University of Turin and City of Health and Science, Turin.
  • Paiar F; Division of Radiation Oncology.
Am J Clin Oncol ; 41(12): 1272-1275, 2018 12.
Article em En | MEDLINE | ID: mdl-29782366
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Organofosforados / Neoplasias Encefálicas / Glioblastoma / Bevacizumab / Antineoplásicos Imunológicos / Recidiva Local de Neoplasia / Compostos de Nitrosoureia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Clin Oncol Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Organofosforados / Neoplasias Encefálicas / Glioblastoma / Bevacizumab / Antineoplásicos Imunológicos / Recidiva Local de Neoplasia / Compostos de Nitrosoureia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Clin Oncol Ano de publicação: 2018 Tipo de documento: Article